| Title |
Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
|
|---|---|
| Published in |
PLOS ONE, August 2012
|
| DOI | 10.1371/journal.pone.0042834 |
| Pubmed ID | |
| Authors |
Viktor von Wyl, Valentina Cambiano, Michael R. Jordan, Silvia Bertagnolio, Alec Miners, Deenan Pillay, Jens Lundgren, Andrew N. Phillips |
| Abstract |
The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ethiopia | 1 | 1% |
| Portugal | 1 | 1% |
| Tanzania, United Republic of | 1 | 1% |
| Unknown | 67 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 23% |
| Researcher | 12 | 17% |
| Student > Ph. D. Student | 11 | 16% |
| Student > Postgraduate | 9 | 13% |
| Student > Bachelor | 4 | 6% |
| Other | 10 | 14% |
| Unknown | 8 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 36% |
| Social Sciences | 6 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Economics, Econometrics and Finance | 5 | 7% |
| Nursing and Health Professions | 4 | 6% |
| Other | 15 | 21% |
| Unknown | 10 | 14% |